Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus

ConditionArterial Thrombosis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-75

SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

Tenecteplase (TNK) is the latest generation of specific thrombolytic drugs independently developed in China. This study aims to investigate the thrombolytic efficacy of platelet membrane-coated tenecteplase (PM-TNK) on human ex vivo arterial thrombi, and to explore the inhibitory effects of plasma from patients receiving antiplatelet therapy on its thrombolytic activity, thereby evaluating the future clinical application value of PM-TNK.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

collection of venous blood or arterial blood

Treatment groups

No treatment groups listed

Sponsors and collaborators

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor

Source ClinicalTrials.gov